| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Institute of Psychiatry, De Crespigny Park (Drs. Prince, Lovestone, Powell, and Mann, and C. Russ); Maudsley Hospital (Dr. Cervilla); Academic Department of Psychiatry, Royal Free Hospital School of Medicine (Dr. Joels); and London School of Hygiene and Tropical Medicine (Dr. Prince), London, UK.
Address correspondence and reprint requests to Dr. Martin Prince, Section of Epidemiology & General Practice, Department of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
OBJECTIVE: The effect of APOE on dementia may be mediated through dyslipidemia and atherogenesis through its effect on cholesterol metabolism. The authors investigated this possibility among aged survivors from the UK Medical Research Council Trial of the Treatment of Hypertension in Older Adults.
DESIGN: A total of 370 of 657 survivors from an initial cohort of 1,088 recruited into the trial between 1983 and 1985 were traced in 1994 and agreed to be screened for dementia. Blood samples were analyzed for APOE genotype and serum fibrinogen. Cholesterol level, smoking behavior, blood pressure, body mass index, and EKG recordings had been measured at recruitment 10 to 12 years earlier. Odds ratios (ORs) for the association between APOE 
4/* and both AD and dementia were estimated and adjusted incrementally for the effect of age and premorbid intelligence, cholesterol, other risk factors for vascular disease, and EKG evidence of cardiovascular disease.
RESULTS: The authors diagnosed 24 cases of National Institute of Neurological and Communicative Disorders and Stroke AD from 41 cases of dementia. The crude OR for the association between APOE 4/* and AD was 3.40 (95% CI 1.30 to 8.91). APOE genotype was associated with serum cholesterol level, and there was a nonsignificant trend for an association with smoking behavior. After adjusting for these and all other vascular risk factors and vascular disease variables listed earlier, the OR for the association between APOE 4/* and AD increased to 4.81 (1.60 to 14.4).
CONCLUSION: Presence of APOE 4/* seems to increase the risk for dementia and AD independently of its effect on dyslipidemia and atherogenesis.
Key words: Epidemiology—Dementia—AD—APOE—Vascular disease
This article has been cited by other articles:
|
|
 |
|
  L. J Whalley, I. J Deary, J. M Starr, K. W Wahle, K. A Rance, V. J Bourne, and H. C Fox n-3 Fatty acid erythrocyte membrane content, APOE {varepsilon}4, and cognitive variation: an observational follow-up study in late adulthood Am. J. Clinical Nutrition, February 1, 2008; 87(2): 449 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. P. Jin, T. Ostbye, J. W. Feightner, S. Di Legge, and V. Hachinski Joint effect of stroke and APOE 4 on dementia risk: The Canadian Study of Health and Aging Neurology, January 1, 2008; 70(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, J. B. Shofer, W. A. Kukull, E. R. Peskind, D. W. Tsuang, J.C.S. Breitner, W. McCormick, J. D. Bowen, L. Teri, G. D. Schellenberg, et al. Serum cholesterol and risk of Alzheimer disease: A community-based cohort study Neurology, October 11, 2005; 65(7): 1045 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Cervilla, M Prince, S Joels, S Lovestone, and A Mann Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1100 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Golomb, M. H. Criqui, H. White, and J. E. Dimsdale Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry Arch Intern Med, January 26, 2004; 164(2): 153 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Honig, M.-X. Tang, S. Albert, R. Costa, J. Luchsinger, J. Manly, Y. Stern, and R. Mayeux Stroke and the Risk of Alzheimer Disease Arch Neurol, December 1, 2003; 60(12): 1707 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. McIlroy, K. B. Dynan, J. T. Lawson, C. C. Patterson, and A. P. Passmore Moderately Elevated Plasma Homocysteine, Methylenetetrahydrofolate Reductase Genotype, and Risk for Stroke, Vascular Dementia, and Alzheimer Disease in Northern Ireland Stroke, October 1, 2002; 33(10): 2351 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kivipelto, E.-L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, S. Iivonen, A. Mannermaa, J. Tuomilehto, A. Nissinen, et al. Apolipoprotein E {epsilon}4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease Ann Intern Med, August 6, 2002; 137(3): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Fillit, R. N. Butler, A. W. O'Connell, M. S. Albert, J. E. Birren, C. W. Cotman, W. T. Greenough, P. E. Gold, A. F. Kramer, L. H. Kuller, et al. Achieving and Maintaining Cognitive Vitality With Aging Mayo Clin. Proc., July 1, 2002; 77(7): 681 - 696. [Abstract] [PDF]
|
|
|
|
 |
|
 R. STEWART Vascular dementia: a diagnosis running out of time The British Journal of Psychiatry, February 1, 2002; 180(2): 152 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Reynish, S. Andrieu, F. Nourhashemi, and B. Vellas Nutritional Factors and Alzheimer's Disease J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2001; 56(11): M675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Golomb, B. Jaworski, B. Wolozin, and G. Siegel Statins and Dementia Arch Neurol, July 1, 2001; 58(7): 1169 - 1170. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Mitochondrial Medicine - Molecular Pathology of Defective Oxidative Phosphorylation Ann. Clin. Lab. Sci., January 1, 2001; 31(1): 25 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A CERVILLA, M. PRINCE, S. LOVESTONE, A. MANN, and S. JOELS Long-term predictors of cognitive outcome in a cohort of older people with hypertension The British Journal of Psychiatry, July 1, 2000; 177(1): 66 - 71. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
